Resmed Inc
RMD
ISIN null / Valor 321632
Resmed Inc
UMushroom community rating:
About company
ResMed Inc. is a global leader in the development and provision of innovative healthcare solutions, particularly focusing on the management and treatment of chronic diseases such as sleep apnea, COPD (Chronic Obstructive Pulmonary Disease), and other related conditions. The company distinguishes itself through its integration of digital health technologies and cloud-connected medical devices, which are designed to transform patient care by keeping individuals out of hospitals and enabling them to lead healthier lives. ResMed's offerings extend beyond individual patient care to include comprehensive software platforms aimed at supporting healthcare professionals and caregivers. These platforms facilitate the delivery of effective care in home or chosen care settings, thereby enhancing the quality of life for patients, reducing the burden of chronic diseases, and contributing to the reduction of healthcare costs. Operating in more than 140 countries, ResMed's approach to healthcare innovation emphasizes the importance of accessibility and efficiency in managing chronic health conditions on a global scale.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (27.10.2025):
Resmed Inc. reported strong financial results for the fourth quarter of fiscal year 2025, demonstrating significant growth in revenue, operating profit, and shareholder returns. The company continues to leverage its market-leading position in sleep and breathing health devices, supported by robust global demand and an expanding digital health ecosystem.
Revenue Growth
Resmed Inc. achieved a 10% year-over-year increase in revenue, reaching $1.3 billion for Q4 FY25. On a constant currency basis, revenue growth stood at 9%, driven by heightened demand for sleep devices and masks, as well as solid performance in the Residential Care Software segment.
Operating Profit Improvement
Operating profit surged by 19% compared to the same quarter last year, with non-GAAP operating profit also up by 19%. This improvement is attributed to enhanced procurement, manufacturing efficiencies, and favorable foreign currency movements, resulting in a gross margin increase of 230 basis points to 60.8%.
Operating Cash Flow and Earnings
The company reported an operating cash flow of $539 million for the quarter. Diluted earnings per share reached $2.58, reflecting a 30% increase from the prior year. Non-GAAP diluted earnings per share also saw a substantial rise of 23% to $2.55.
Dividend Increase
Resmed Inc. declared a quarterly dividend of $0.60 per share, marking a 13% increase. This dividend will be paid to shareholders on September 18, 2025, underscoring the company's commitment to delivering value to its investors.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
35683 M
Market cap (USD)
1,008,371
Daily traded volume (Shares)
232.18 / 228.6
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
